These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27859371)

  • 1. Activity limitations in myasthenia gravis and relation to clinical variables.
    De Meel RHP; Lipka AF; Van Der Lende M; Van Zwet EW; Tannemaat MR; Verschuuren JJGM
    Muscle Nerve; 2017 Jul; 56(1):64-70. PubMed ID: 27859371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.
    de Meel RHP; Raadsheer WF; van Zwet EW; Verschuuren JJGM; Tannemaat MR
    Eur J Neurol; 2019 Jun; 26(6):947-950. PubMed ID: 30417962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paroxysmal supraventricular tachycardia in anti-musk Myasthenia gravis: A case report.
    Di Giovanni M; Battisti C; Salvatore S; Tumminelli G; Vinciguerra C; Ruocco G; Federico A
    J Neurol Sci; 2016 Oct; 369():250-251. PubMed ID: 27653899
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity.
    Bedlack RS; Simel DL; Bosworth H; Samsa G; Tucker-Lipscomb B; Sanders DB
    Neurology; 2005 Jun; 64(11):1968-70. PubMed ID: 15955957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.
    Huijbers MG; Vink AF; Niks EH; Westhuis RH; van Zwet EW; de Meel RH; Rojas-García R; Díaz-Manera J; Kuks JB; Klooster R; Straasheijm K; Evoli A; Illa I; van der Maarel SM; Verschuuren JJ
    J Neuroimmunol; 2016 Feb; 291():82-8. PubMed ID: 26857500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical features of myasthenia related with autoantibodies to muscle specific tyrosine kinase (MuSK)].
    Sanadze AG; Sidnev DV; Karganov MIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):72-6. PubMed ID: 21311492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dropped head syndrome as prominent clinical feature in MuSK-positive Myasthenia Gravis with thymus hyperplasia.
    Spengos K; Vassilopoulou S; Papadimas G; Tsivgoulis G; Karandreas N; Zambelis T; Manta P
    Neuromuscul Disord; 2008 Feb; 18(2):175-7. PubMed ID: 18053719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vocal cord paralysis in myasthenia gravis with anti-MuSK antibodies.
    Hara K; Mashima T; Matsuda A; Tanaka K; Tomita M; Shiraishi H; Motomura M; Nishizawa M
    Neurology; 2007 Feb; 68(8):621-2. PubMed ID: 17310039
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.
    Díaz-Manera J; Rojas-García R; Gallardo E; Juárez C; Martínez-Domeño A; Martínez-Ramírez S; Dalmau J; Blesa R; Illa I
    Nat Clin Pract Neurol; 2007 Jul; 3(7):405-10. PubMed ID: 17611489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.
    de Meel RHP; Barnett C; Bril V; Tannemaat MR; Verschuuren JJGM
    J Neuromuscul Dis; 2020; 7(3):297-300. PubMed ID: 32250313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts.
    Guptill JT; Sanders DB; Evoli A
    Muscle Nerve; 2011 Jul; 44(1):36-40. PubMed ID: 21674519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia Gravis: Unusual Presentations and Diagnostic Pitfalls.
    Rodolico C; Parisi D; Portaro S; Biasini F; Sinicropi S; Ciranni A; Toscano A; Messina S; Musumeci O; Vita G; Girlanda P
    J Neuromuscul Dis; 2016 Aug; 3(3):413-418. PubMed ID: 27854225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MG with distal muscle involvement.
    Iwasaki Y; Igarashi O; Kawabe K; Kiyozuka T; Kawase Y; Aoyagi J; Iwasa Y; Hirano K; Satoh R; Ikeda K
    Acta Neurol Scand; 2004 Oct; 110(4):270; author reply 271-2. PubMed ID: 15355493
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoimmune myasthenia gravis in childhood.
    Andrews PI
    Semin Neurol; 2004 Mar; 24(1):101-10. PubMed ID: 15229797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MuSK-Ab positive myasthenia: not always grave.
    Zouvelou V; Stamboulis E; Skriapa L; Tzartos SJ
    J Neurol Sci; 2013 Aug; 331(1-2):150-1. PubMed ID: 23706725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bread-and-butter in diagnosis of myasthenia gravis.
    Chan AY; Liu DT
    Arch Neurol; 2005 Dec; 62(12):1939; author reply 1939-40. PubMed ID: 16344357
    [No Abstract]   [Full Text] [Related]  

  • 19. Complicating autoimmune diseases in myasthenia gravis: a review.
    Nacu A; Andersen JB; Lisnic V; Owe JF; Gilhus NE
    Autoimmunity; 2015; 48(6):362-8. PubMed ID: 25915571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.